ASTRAZENECA PLC ADR

NASDAQ: AZN (Astrazeneca PLC)

Last update: 23 Sep, 5:02PM

77.14

-1.24 (-1.58%)

  • 1D -1.58%
  • 5D 14.45%
  • 1M 20.04%
  • 6M -2.21%
  • YTD 12.78%
  • 1Y 16.35%
  • 5Y 54.62%
Previous Close 78.38
Open 77.24
Volume 3,788,214
Avg. Volume (3M) 4,388,519
Market Cap 239,634,644,992
Price / Earnings (TTM) 37.45
Price / Earnings (Forward) 14.58
Price / Sales 4.16
Price / Book 5.19
52 Weeks Range
60.47 (-21%) — 87.68 (13%)
Earnings Date 12 Nov 2024
TTM Dividend Yield 1.93%
Profit Margin 12.68%
Operating Margin (TTM) 20.40%
Diluted EPS (TTM) 2.07
Quarterly Revenue Growth (YOY) 18.00%
Quarterly Earnings Growth (YOY) 4.00%
Total Debt/Equity (MRQ) 77.47%
Current Ratio (MRQ) 0.930
Operating Cash Flow (TTM) 11.33 B
Levered Free Cash Flow (TTM) 9.51 B
Return on Assets (TTM) 8.50%
Return on Equity (TTM) 16.66%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Bullish
Drug Manufacturers - General (Global) Bullish Bullish
Stock Astrazeneca PLC Bullish Bullish

AIStockmoo Score

1.3
Analyst Consensus 2.0
Insider Activity NA
Price Volatility 2.0
Technical Moving Averages 1.5
Technical Oscillators -0.5
Average 1.25

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
AZN 240 B 1.93% 37.45 5.19
SNY 120 B 8.54% 25.24 1.55
AMGN 143 B 3.38% 34.01 19.33
GILD 113 B 3.40% 1,005.44 6.21
GRFS 6 B - 32.20 0.830
BIIB 23 B - 14.35 1.31

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Growth
% Held by Institutions 16.76%

No data within this time range.

No data within this time range.

  • 3M
Date Type Details
18 Dec 2024 CNBC Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
12 Dec 2024 Announcement Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development
11 Dec 2024 Announcement LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
09 Dec 2024 Announcement Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
08 Dec 2024 Announcement Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial
06 Dec 2024 Announcement IMFINZI® (durvalumab) granted Priority Review in the US ​for patients with muscle-invasive bladder cancer
05 Dec 2024 Announcement IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
25 Nov 2024 Announcement TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
20 Nov 2024 Announcement AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
18 Nov 2024 Announcement GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
12 Nov 2024 Announcement AstraZeneca’s 9M and Q3 2024 results
12 Nov 2024 Announcement AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
08 Nov 2024 Announcement TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
07 Nov 2024 Announcement AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024
18 Oct 2024 CNBC Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
07 Oct 2024 Announcement AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
03 Oct 2024 Announcement CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
02 Oct 2024 Announcement Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
01 Oct 2024 Announcement ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
26 Sep 2024 Announcement TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
23 Sep 2024 Announcement Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
Show more
TTM Dividend Yield 1.93%
5Y Average Dividend Yield 2.46%
Payout Ratio 71.57%
Expected Next Dividend Payment Mar 2025
Ex Date Announcement Date Payment Date Details
09 Aug 2024 25 Jul 2024 09 Sep 2024 0.5 Cash
22 Feb 2024 08 Feb 2024 25 Mar 2024 0.985 Cash
10 Aug 2023 28 Jul 2023 11 Sep 2023 0.465 Cash
23 Feb 2023 09 Feb 2023 27 Mar 2023 0.985 Cash
11 Aug 2022 29 Jul 2022 12 Sep 2022 0.465 Cash
24 Feb 2022 10 Feb 2022 28 Mar 2022 0.985 Cash
12 Aug 2021 29 Jul 2021 13 Sep 2021 0.45 Cash
25 Feb 2021 11 Feb 2021 29 Mar 2021 0.95 Cash
13 Aug 2020 30 Jul 2020 14 Sep 2020 0.45 Cash
27 Feb 2020 14 Feb 2020 30 Mar 2020 0.95 Cash
08 Aug 2019 29 Jul 2019 09 Sep 2019 0.45 Cash
28 Feb 2019 14 Feb 2019 27 Mar 2019 0.95 Cash
09 Aug 2018 26 Jul 2018 10 Sep 2018 0.45 Cash
15 Feb 2018 02 Feb 2018 19 Mar 2018 0.95 Cash
09 Aug 2017 28 Jul 2017 11 Sep 2017 0.45 Cash
15 Feb 2017 02 Feb 2017 20 Mar 2017 0.95 Cash
10 Aug 2016 28 Jul 2016 12 Sep 2016 0.45 Cash
17 Feb 2016 05 Feb 2016 21 Mar 2016 0.95 Cash
12 Aug 2015 30 Jul 2015 14 Sep 2015 0.45 Cash
18 Feb 2015 09 Feb 2015 23 Mar 2015 1.9 Cash
13 Aug 2014 31 Jul 2014 15 Sep 2014 0.9 Cash
19 Feb 2014 07 Feb 2014 24 Mar 2014 1.9 Cash
14 Aug 2013 01 Aug 2013 16 Sep 2013 0.9 Cash
13 Feb 2013 31 Jan 2013 18 Mar 2013 1.9 Cash
08 Aug 2012 26 Jul 2012 10 Sep 2012 0.9 Cash
15 Feb 2012 02 Feb 2012 19 Mar 2012 1.95 Cash
04 Aug 2011 28 Jul 2011 12 Sep 2011 0.85 Cash
02 Feb 2011 27 Jan 2011 14 Mar 2011 1.85 Cash
04 Aug 2010 29 Jul 2010 13 Sep 2010 0.7 Cash
03 Feb 2010 28 Jan 2010 15 Mar 2010 1.71 Cash
05 Aug 2009 30 Jul 2009 14 Sep 2009 0.59 Cash
04 Feb 2009 29 Jan 2009 16 Mar 2009 1.5 Cash
06 Aug 2008 31 Jul 2008 15 Sep 2008 0.55 Cash
07 Feb 2008 04 Feb 2008 17 Mar 2008 1.35 Cash
08 Aug 2007 27 Jul 2007 17 Sep 2007 0.52 Cash
07 Feb 2007 01 Feb 2007 19 Mar 2007 1.23 Cash
09 Aug 2006 27 Jul 2006 18 Sep 2006 0.49 Cash
08 Feb 2006 02 Feb 2006 20 Mar 2006 0.92 Cash
10 Aug 2005 29 Jul 2005 19 Sep 2005 0.38 Cash
09 Feb 2005 27 Jan 2005 21 Mar 2005 0.645 Cash
11 Aug 2004 22 Jul 2004 20 Sep 2004 0.295 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2024 1.49 2 1.93
2023 1.45 2 2.15
2022 1.45 2 2.14
2021 1.40 2 2.40
2020 1.40 2 2.80
2019 1.40 2 2.81
2018 1.40 2 3.69
2017 1.40 2 4.04
2016 1.40 2 5.12
2015 2.35 2 6.92
2014 2.80 2 7.96
2013 2.80 2 9.43
2012 2.85 2 12.06
2011 2.70 2 11.67
2010 2.41 2 10.44
2009 2.09 2 8.91
2008 1.90 2 9.26
2007 1.75 2 8.17
2006 1.41 2 5.27
2005 1.03 2 4.22
2004 0.295 1 1.62
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria